MedTrace Logo

PDT For Induction Therapy For Head And Neck Cancer

NCT07214987 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-01-30

No results posted yet for this study

Summary

This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

Conditions

Interventions

DRUG

Toripalimab-tpzi

Toripalimab-tpzi is a humanized IgG4 monoclonal antibody specific against human PD-1.

DRUG

Cisplatin

Cisplatin is an injectable chemotherapy agent classified as a platinum-based alkylating agent.

DRUG

Docetaxel

Docetaxel is a taxane chemotherapy agent.

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Thomas Roberts, MD, MBA · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2027-12-31
Completion
2029-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07214987 on ClinicalTrials.gov